de Jong, Madelon M. E.
Kellermayer, Zoltán http://orcid.org/0000-0001-9560-6424
Papazian, Natalie
Tahri, Sabrin
Hofste op Bruinink, Davine http://orcid.org/0000-0002-1296-120X
Hoogenboezem, Remco
Sanders, Mathijs A.
van de Woestijne, Pieter C.
Bos, P. Koen
Khandanpour, Cyrus
Vermeulen, Jessica
Moreau, Philippe
van Duin, Mark
Broijl, Annemiek
Sonneveld, Pieter http://orcid.org/0000-0002-0808-2237
Cupedo, Tom http://orcid.org/0000-0003-1095-4273
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme
Deutsche Krebshilfe
European Myeloma Foundation
Article History
Received: 25 June 2020
Accepted: 9 April 2021
First Online: 20 May 2021
Competing interests
: J.V. is an employee of Janssen; A.B. consults for Celgene, Janssen, Amgen and Takeda; P.S. consults for and receives research support from Celgene, Janssen, Karyopharm and SkylineDx; P.M. is on the advisory boards of and receives honoraria from Janssen, BMS/Celgene, Amgen and Abbvie. The remaining authors declare no competing interests.